{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:42:11Z","timestamp":1780083731061,"version":"3.54.0"},"reference-count":159,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Given the high whittling down rates, high costs, and moderate pace of new medication, revelation, and improvement, repurposing \u201cold\u201d drugs to treat typical and uncommon illnesses is progressively becoming an appealing proposition. Drug repurposing is the way toward utilizing existing medications in treating diseases other than the purposes they were initially designed for. Faced with scientific and economic challenges, the prospect of discovering new medication indications is enticing to the pharmaceutical sector. Medication repurposing can be used at various stages of drug development, although it has shown to be most promising when the drug has previously been tested for safety. We describe strategies of drug repurposing for Parkinson\u2019s disease, which is a neurodegenerative condition that primarily affects dopaminergic neurons in the substantia nigra. We also discuss the obstacles faced by the repurposing community and suggest new approaches to solve these challenges so that medicine repurposing can reach its full potential.<\/jats:p>","DOI":"10.3389\/fphar.2022.1028356","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T07:28:11Z","timestamp":1666769291000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Drug reprofiling history and potential therapies against Parkinson\u2019s disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Komal","family":"Latif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiia D.","family":"Shkodina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmytro I.","family":"Boiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakia","family":"Rafique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrah S.","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Alfaleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Md.","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s10534-018-0131-5","article-title":"Prevention of progression in Parkinson's disease","volume":"31","author":"Aaseth","year":"2018","journal-title":"Biometals"},{"key":"B2","doi-asserted-by":"publisher","first-page":"s2","DOI":"10.4172\/2329-6887.s2-e002","article-title":"Advantages and challenges in drug Re-profiling","volume":"383","author":"Agrawal","year":"2015","journal-title":"J. Pharmacovigil."},{"key":"B3","article-title":"LRRK2 kinase in Parkinson\u2019s disease","author":"Alessi","year":"2022","journal-title":"Neurodegeneration"},{"key":"B4","doi-asserted-by":"publisher","first-page":"E100","DOI":"10.3390\/biom9030100","article-title":"Omega-3 fatty acids prevent post-traumatic stress disorder-induced memory impairment","volume":"9","author":"Alquraan","year":"2019","journal-title":"Biomolecules"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: Challenges and opportunities in drug discovery.discovery: Miniperspective","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1586\/ern.09.48","article-title":"Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: Selection criteria and patient management. Disease: Selection criteria and patient management","volume":"9","author":"Antonini","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40263-018-0548-y","article-title":"Drug repurposing in Parkinson's disease","volume":"32","author":"Athauda","year":"2018","journal-title":"CNS Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2014.226","article-title":"The ongoing pursuit of neuroprotective therapies in Parkinson disease","volume":"11","author":"Athauda","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"B11","first-page":"879","article-title":"Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies","volume":"152","author":"Baba","year":"1998","journal-title":"Am. J. Pathol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"Balestrino","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1016\/j.jmb.2018.08.019","article-title":"Ursodeoxycholic acid improves mitochondrial function and redistributes Drp1 in fibroblasts from patients with either sporadic or familial alzheimer's disease","volume":"430","author":"Bell","year":"2018","journal-title":"J. Mol. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.004","article-title":"The function of \u03b1-synuclein","volume":"79","author":"Bendor","year":"2013","journal-title":"Neuron"},{"key":"B16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejphar.2003.11.065","article-title":"Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque","volume":"485","author":"Bezard","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"B17","article-title":"Parkinson\u2019s disease: Biochemistry, clinical pathology, and treatment","author":"Birkmayer","year":"2012"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s00702-018-1913-1","article-title":"Tetracycline repurposing in neurodegeneration: Focus on Parkinson's disease","volume":"125","author":"Bortolanza","year":"2018","journal-title":"J. Neural Transm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neuropharm.2018.04.005","article-title":"Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease","volume":"147","author":"Bourque","year":"2019","journal-title":"Neuropharmacology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3233\/JPD-171191","article-title":"c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential. Parkinson\u2019s disease: mechanisms and therapeutic potential","volume":"7","author":"Brahmachari","year":"2017","journal-title":"J. Park. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/cells10020375","article-title":"Alpha-Synuclein: Mechanisms of release and pathology progression in synucleinopathies.n synucleinopathies. Cells","volume":"10","author":"Br\u00e1s","year":"2021","journal-title":"Cells"},{"key":"B22","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.drudis.2010.08.014","article-title":"L-DOPA-induced dyskinesia in Parkinson's disease: A drug discovery perspective.perspective","volume":"15","author":"Buck","year":"2010","journal-title":"Drug Discov. Today"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/s1471-1931(00)00017-3","article-title":"Electrophysiology of dopamine in normal and denervated striatal neurons. striatal neurons","volume":"23","author":"Calabresi","year":"2000","journal-title":"Trends Neurosci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1177\/1740774506073173","article-title":"Clinical trials bureaucracy: Unintended consequences of well-intentioned policy","volume":"3","author":"Califf","year":"2006","journal-title":"Clin. Trials"},{"key":"B25","doi-asserted-by":"publisher","first-page":"212553","DOI":"10.7573\/dic.212553","article-title":"The therapeutic role of minocycline in Parkinson's disease","volume":"8","author":"Cankaya","year":"2019","journal-title":"Drugs Context"},{"key":"B26","article-title":"Neurological disorders","author":"Chandra","year":"2006","journal-title":"Dis. control priorities"},{"key":"B27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic Signal."},{"key":"B28","doi-asserted-by":"publisher","first-page":"161S-173S","DOI":"10.1592\/phco.27.12part2.161S","article-title":"Pharmacotherapy for Parkinson's disease","volume":"27","author":"Chen","year":"2007","journal-title":"Pharmacother. Hum. Pharmacol. Drug Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00406-019-00982-6","article-title":"Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?","volume":"269","author":"Crippa","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jad.2008.03.008","article-title":"Depression in Parkinson's disease: A double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation","volume":"111","author":"da Silva","year":"2008","journal-title":"J. Affect. Disord."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e36455","DOI":"10.1371\/journal.pone.0036455","article-title":"Genetic characterization of human influenza viruses in the pandemic (2009-2010) and post-pandemic (2010-2011) periods in Japan. characterization of human influenza viruses in the pandemic (2009\u20132010) and post-pandemic (2010\u20132011) periods in Japan","volume":"7","author":"Dapat","year":"2012","journal-title":"PloS one"},{"key":"B32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2165\/00003088-200241040-00003","article-title":"Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. properties of drugs used in the treatment of Parkinson\u2019s disease","volume":"41","author":"Deleu","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jnutbio.2019.02.012","article-title":"N-acetylcysteine and alpha-lipoic acid improve antioxidant defenses and decrease oxidative stress, inflammation and serum lipid levels in ovariectomized rats via estrogen-independent mechanisms","volume":"67","author":"Delgobo","year":"2019","journal-title":"J. Nutr. Biochem."},{"key":"B34","first-page":"504","article-title":"Parkinson\u2019s disease and its management: Part 1: Disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis","volume":"40","author":"DeMaagd","year":"2015","journal-title":"P Trans."},{"key":"B35","first-page":"668","article-title":"Parkinson\u2019s disease and its management: Part 3: Nondopaminergic and nonpharmacological treatment options","volume":"40","author":"DeMaagd","year":"2015","journal-title":"P Trans."},{"key":"B36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4103\/1658-354X.115328","article-title":"Comparison of the antiemetic effect of ramosetron with the combination of dexamethasone and ondansetron in middle ear surgery: A double-blind, randomized clinical study. Ramosetron with the combination of dexamethasone and ondansetron in middle ear surgery: A double-blind, randomized clinical study","volume":"7","author":"Desai","year":"2013","journal-title":"Saudi J. Anaesth."},{"key":"B37","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40263-019-00651-1","article-title":"Effects of renal impairment on the pharmacokinetics of once-daily amantadine extended-release tablets. Pharmacokinetics of once-daily amantadine extended-release tablets","volume":"33","author":"deVries","year":"2019","journal-title":"CNS drugs"},{"key":"B38","article-title":"Drug repurposing and orphan disease therapeutics. Drug Repurposing-Hypothesis","author":"Dhir","year":"2020","journal-title":"Mol. Aspects Ther. Appl. IntechOpen"},{"key":"B39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/JPD-130230","article-title":"The role of oxidative stress in Parkinson's disease","volume":"3","author":"Dias","year":"2013","journal-title":"J. Park. Dis."},{"key":"B40","article-title":"Amantadine as an antiviral agent in influenza","author":"Douglas","year":"1982","journal-title":"Mass Med. Soc."},{"key":"B41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1006\/exnr.2002.8023","article-title":"The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeys","volume":"178","author":"Eberling","year":"2002","journal-title":"Exp. Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41563-019-0338-z","article-title":"Exploiting machine learning for end-to-end drug discovery and development. for end-to-end drug discovery and development","volume":"18","author":"Ekins","year":"2019","journal-title":"Nat. Mat."},{"key":"B43","first-page":"157","article-title":"Drug repositioning: Concept, classification, methodology, and importance in rare\/orphans and neglected diseases","author":"Emanuel Almeida Moreira de Oliveira1","year":"2018","journal-title":"J. Appl. Pharm. Sci."},{"key":"B44","first-page":"157","article-title":"Drug repositioning: Concept, classification, methodology, and importance in rare\/orphans and neglected diseases","author":"Emanuel","year":"2018","journal-title":"J. Appl. Pharm. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4236\/ojd.2017.62004","article-title":"Monoamine oxidase inhibitors\u2014Revisiting a therapeutic principle","volume":"6","author":"Entzeroth","year":"2017","journal-title":"Open J. Depress."},{"key":"B46","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1001\/jamaneurol.2019.3983","article-title":"The narrowing path for nilotinib and other potential disease-modifying therapies for Parkinson disease. Disease-modifying therapies for Parkinson disease","volume":"77","author":"Espay","year":"2020","journal-title":"JAMA Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2003.tb07458.x","article-title":"Description of Parkinson's disease as a clinical syndrome","volume":"991","author":"Fahn","year":"2003","journal-title":"Ann. N. Y. Acad. Sci. Acad. Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.therap.2020.02.006","article-title":"Drug repurposing in rare diseases: Myths and reality","volume":"75","author":"Fetro","year":"2020","journal-title":"Therapie"},{"key":"B49","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/s1353-8020(03)00040-3","article-title":"Malignant melanoma and levodopa in Parkinson's disease: Causality or coincidence?","volume":"9","author":"Fiala","year":"2003","journal-title":"Park. Relat. Disord."},{"key":"B50","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00131746-200407000-00005","article-title":"The role of monoamine oxidase inhibitors in current psychiatric practice","volume":"10","author":"Fiedorowicz","year":"2004","journal-title":"J. Psychiatr. Pract."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e00841","DOI":"10.1002\/prp2.841","article-title":"Drug repurposing strategies of relevance for Parkinson's disease. Parkinson\u2019s disease","volume":"9","author":"Fletcher","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"B52","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3233\/JPD-150630","article-title":"Immunotherapy in Parkinson's disease: Micromanaging alpha-synuclein aggregation. Aggregation","volume":"5","author":"George","year":"2015","journal-title":"J. Park. Dis."},{"key":"B53","article-title":"Discovering cures in medicine: The thalidomide case","author":"Gillies","year":"2016","journal-title":"Medicine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd1383","article-title":"Inflammatory resolution: New opportunities for drug discovery. Drug discovery","volume":"3","author":"Gilroy","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1111\/j.1582-4934.2008.00402.x","article-title":"Neuronal cell death in neurodegenerative diseases: Recurring themes around protein handling","volume":"12","author":"Gorman","year":"2008","journal-title":"J. Cell. Mol. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1358\/dnp.2009.22.1.1303754","article-title":"The year's new drugs & biologics - 2008. biologics\u20142008","volume":"22","author":"Graul","year":"2009","journal-title":"Drug News Perspect."},{"key":"B57","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.amjopharm.2006.12.001","article-title":"Rasagiline (TVP-1012): A new selective monoamine oxidase inhibitor for Parkinson's disease","volume":"4","author":"Guay","year":"2006","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s11030-021-10217-3","article-title":"Artificial intelligence to deep learning: Machine intelligence approach for drug discovery. Deep learning: Machine intelligence approach for drug discovery","volume":"25","author":"Gupta","year":"2021","journal-title":"Mol. Divers."},{"key":"B59","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/jnc.12751","article-title":"Dyskinesia in Parkinson's disease: Mechanisms and current non\u2010pharmacological interventions","volume":"130","author":"Heumann","year":"2014","journal-title":"J. Neurochem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fpsyt.2018.00091","article-title":"Medications used for cognitive enhancement in patients with schizophrenia, bipolar disorder, Alzheimer\u2019s disease, and Parkinson\u2019s disease","volume":"9","author":"Hsu","year":"2018","journal-title":"Front. Psychiatry"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.0b013e31824e8f0d","article-title":"Amantadine: The journey from fighting flu to treating Parkinson disease","volume":"78","author":"Hubsher","year":"2012","journal-title":"Neurology"},{"key":"B62","doi-asserted-by":"crossref","DOI":"10.1145\/3307339.3342185","article-title":"Multivariate multi-step deep learning time series approach in forecasting Parkinson's disease future severity progression","author":"Ismail","year":"2019"},{"key":"B63","doi-asserted-by":"crossref","DOI":"10.1002\/9780470017975","volume-title":"Prescribing for elderly patients","author":"Jackson","year":"2009"},{"key":"B64","volume-title":"Studies on alpha-synuclein aggregation and the effect of dietary curcumin derivative: Relevance to Parkinson\u2019s disease","author":"Jagannatha Rao","year":"2007"},{"key":"B65","first-page":"497","article-title":"1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates. of Parkinson's disease, with emphasis on mice and nonhuman primates","volume":"54","author":"Jakowec","year":"2004","journal-title":"Comp. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","article-title":"Toward better drug repositioning: Prioritizing and integrating existing methods into efficient pipelines. Methods into efficient pipelines","volume":"19","author":"Jin","year":"2014","journal-title":"Drug Discov. Today"},{"key":"B67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuropharm.2018.05.035","article-title":"Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease. treat l-DOPA-induced dyskinesia in Parkinson's disease","volume":"147","author":"Johnston","year":"2019","journal-title":"Neuropharmacology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/ane.12563","article-title":"The genetic background of Parkinson's disease: Current progress and future prospects. Current progress and future prospects","volume":"134","author":"Kalinderi","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"B69","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s10038-018-0558-0","article-title":"Treatment of two mitochondrial disease patients with a combination of febuxostat and inosine that enhances cellular ATP","volume":"64","author":"Kamatani","year":"2019","journal-title":"J. Hum. Genet."},{"key":"B70","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2165\/00003088-200039040-00001","article-title":"Clinical pharmacokinetics of ropinirole","volume":"39","author":"Kaye","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.drudis.2012.05.007","article-title":"Drug discovery in pharmaceutical industry: Productivity challenges and trends","volume":"17","author":"Khanna","year":"2012","journal-title":"Drug Discov. Today"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00702-017-1707-x","article-title":"Classification of advanced stages of Parkinson's disease: Translation into stratified treatments.advanced stages of Parkinson\u2019s disease: Translation into stratified treatments","volume":"124","author":"Kr\u00fcger","year":"2017","journal-title":"J. Neural Transm."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","article-title":"Drug repositioning and repurposing: Terminology and definitions in literature. Repurposing: Terminology and definitions in literature","volume":"20","author":"Langedijk","year":"2015","journal-title":"Drug Discov. Today"},{"key":"B74","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/mds.27965","article-title":"Pierre D. And the first photographs of Parkinson's disease Parkinson's disease","volume":"35","author":"Lewis","year":"2020","journal-title":"Mov. Disord."},{"key":"B75","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/wnf.0b013e318154c7c4","article-title":"Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease","volume":"30","author":"LeWitt","year":"2007","journal-title":"Clin. Neuropharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fnagi.2016.00254","article-title":"c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's Disease. enable insights into the pathophysiology and neuroprotection in Parkinson\u2019s disease","volume":"8","author":"Lindholm","year":"2016","journal-title":"Front. Aging Neurosci. Neurosci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-pharmtox-010818-021214","article-title":"The potential of L-type calcium channels as a drug target for neuroprotective therapy in Parkinson's disease","volume":"59","author":"Liss","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1056\/NEJM200006153422407","article-title":"Erectile dysfunction","volume":"342","author":"Lue","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11481-018-09831-0","article-title":"Beta2-Adrenoceptor agonists in Parkinson\u2019s disease and other synucleinopathies","volume":"15","author":"Magistrelli","year":"2019","journal-title":"J. Neuroimmune Pharmacol."},{"key":"B80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-017-0099-z","article-title":"Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments","volume":"6","author":"Maiti","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"B81","doi-asserted-by":"publisher","first-page":"E1585","DOI":"10.3390\/ijms17091585","article-title":"Protein kinases and Parkinson's disease. Kinases and Parkinson's disease","volume":"17","author":"Mehdi","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1213\/00000539-198502000-00008","article-title":"Principles of neuroanesthesia for the nonneurosurgical patient with CNS pathophysiology nonneurosurgical patient with CNS pathophysiology","volume":"64","author":"Messick","year":"1985","journal-title":"Anesth. Analg."},{"key":"B83","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/jb\/mvr032","article-title":"Drug discovery and development focusing on existing medicines: Drug re-profiling strategy. Profiling strategy","volume":"149","author":"Mizushima","year":"2011","journal-title":"J. Biochem."},{"key":"B84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-8-47","article-title":"Significance of the parkin and PINK1 gene in Jordanian families with incidences of young-onset and juvenile parkinsonism","volume":"8","author":"Myhre","year":"2008","journal-title":"BMC Neurol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s10654-020-00648-x","article-title":"Influence of periodontal disease on risk of dementia: A systematic literature review and a meta-analysis. Disease on risk of dementia: A systematic literature review and a meta-analysis","volume":"35","author":"Nadim","year":"2020","journal-title":"Eur. J. Epidemiol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jns.2018.11.005","article-title":"Effect of istradefylline on mood disorders in Parkinson's disease","volume":"396","author":"Nagayama","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00702-020-02150-w","article-title":"Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate \u03b1-synuclein cytotoxicity in disease-modifying therapy for Parkinson\u2019s disease","volume":"127","author":"Naoi","year":"2020","journal-title":"J. Neural Transm."},{"key":"B88","article-title":"Therapeutic drug repurposing, repositioning and rescue","volume":"57","author":"Naylor","year":"2015","journal-title":"Drug Discov."},{"key":"B89","article-title":"Emerging therapies in the pharmacological treatment of Parkinson\u2019s disease","author":"Nussbaum","year":"2002","journal-title":"Adis Int. Ltd."},{"key":"B90","article-title":"Pharmacotherapy for Parkinson's disease-observations and innovations","author":"Nyholm","year":"2003","journal-title":"Acta Univ. Ups."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nrd1900","article-title":"Finding new tricks for old drugs: An efficient route for public-sector drug discovery. Drug discovery","volume":"4","author":"O'Connor","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"B92","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/jnc.13750","article-title":"Current and experimental treatments of Parkinson disease: A guide for neuroscientists","volume":"139","author":"Oertel","year":"2016","journal-title":"J. Neurochem."},{"key":"B93","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000119538","article-title":"Levodopa and dopamine agonists in the treatment od Parkinson's disease: Advantages and disadvantages","volume":"34","author":"Ogawa","year":"1994","journal-title":"Neuroscience"},{"key":"B94","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000119538","article-title":"Levodopa and dopamine agonists in the treatment of Parkinson\u2019s disease: Advantages and disadvantages","volume":"34","author":"Ogawa","year":"1994","journal-title":"Eur. Neurol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies. in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J. Park. Dis."},{"key":"B96","first-page":"159","volume-title":"Therapeutic application of stem cell and gene therapy in Parkinson\u2019s disease","author":"Palmer","year":"2019"},{"key":"B97","first-page":"30","article-title":"Parkinson\u2019s disease : Recent advances","volume-title":"J. Assoc. Phys. India","author":"Pandey","year":"2012"},{"key":"B98","doi-asserted-by":"publisher","first-page":"k2701","DOI":"10.1136\/bmj.k2701","article-title":"New uses for old drugs","volume":"361","author":"Pantziarka","year":"2018","journal-title":"BMJ"},{"key":"B99","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/ejn.14109","article-title":"Cell-based therapy for Parkinson's disease: A journey through decades toward the light side of the force","volume":"49","author":"Parmar","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: A promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"key":"B101","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","article-title":"Non-motor symptoms in Parkinson's disease","volume":"22","author":"Pfeiffer","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"B102","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S1353-8020(09)70831-4","article-title":"The clinical progression of Parkinson's disease. related disorders","volume":"15","author":"Poewe","year":"2009","journal-title":"Park. Relat. Disord."},{"key":"B103","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.drudis.2018.11.022","article-title":"The drug repurposing landscape from 2012 to 2017: Evolution, challenges, and possible solutions. Challenges, and possible solutions","volume":"24","author":"Polamreddy","year":"2019","journal-title":"Drug Discov. Today"},{"key":"B104","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations. Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B105","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1517\/17425250903105420","article-title":"Rivastigmine in Parkinson\u2019s disease dementia","volume":"5","author":"Rao","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson's disease and other movement disorders","volume":"20","author":"Rascol","year":"2021","journal-title":"Lancet. Neurol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrd3478","article-title":"Trends in the exploitation of novel drug targets","volume":"10","author":"Rask-Andersen","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"B108","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.tins.2021.12.002","article-title":"LRRK2 and idiopathic Parkinson's disease. Parkinson\u2019s disease","volume":"45","author":"Rocha","year":"2022","journal-title":"Trends Neurosci."},{"key":"B109","first-page":"1","article-title":"Drug Repurposing (DR): An Emerging Approach in Drug Discovery","author":"Rudrapal","year":"2020","journal-title":"Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications"},{"key":"B110","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s12640-019-00015-z","article-title":"The neuroprotective effect of doxycycline on neurodegenerative diseases","volume":"35","author":"Santa-Cecilia","year":"2019","journal-title":"Neurotox. Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40265-019-01104-1","article-title":"Targeting \u03b1-synuclein in Parkinson\u2019s disease: Progress towards the development of disease-modifying therapeutics","volume":"79","author":"Savitt","year":"2019","journal-title":"Drugs"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40263-014-0205-z","article-title":"Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease. induced dyskinesia in patients with Parkinson\u2019s disease","volume":"28","author":"Schaeffer","year":"2014","journal-title":"CNS drugs"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1136\/jnnp.2004.035980","article-title":"Present and future drug treatment for Parkinson\u2019s disease","volume":"76","author":"Schapira","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry Neurosurg. Psychiatry"},{"key":"B114","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1474-4422(07)70327-7","article-title":"Mitochondria in the aetiology and pathogenesis of Parkinson's disease","volume":"7","author":"Schapira","year":"2008","journal-title":"Lancet. Neurol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/med.21627","article-title":"Repurposing approved drugs on the pathway to novel therapies","volume":"40","author":"Schein","year":"2020","journal-title":"Med. Res. Rev."},{"key":"B116","article-title":"Therapeutic drug repurposing, repositioning and rescue","author":"Schonfeld","year":"2014","journal-title":"Drug Discov. World Winter"},{"key":"B117","article-title":"Repositioning drugs and biologics: Retargeting old\/existing drugs for potential new therapeutic applications","volume":"4","author":"Sekhon","year":"2013","journal-title":"J. Pharm. Educ. Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"key":"B119","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2147\/TCRM.S144481","article-title":"Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease. dyskinesia in patients with Parkinson\u2019s disease","volume":"14","author":"Sharma","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"B120","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/acn3.76","article-title":"Overcoming obstacles to repurposing for neurodegenerative disease. obstacles to repurposing for neurodegenerative disease","volume":"1","author":"Shineman","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"136675","DOI":"10.1016\/j.neulet.2022.136675","article-title":"Cognitive and affective disturbances in patients with Parkinson's disease: Perspectives for classifying of motor\/neuropsychiatric subtypes. affective disturbances in patients with Parkinson's disease: Perspectives for classifying of motor\/neuropsychiatric subtypes","volume":"781","author":"Shkodina","year":"2022","journal-title":"Neurosci. Lett."},{"key":"B122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-019-1252-3","article-title":"Ambroxol as a novel disease-modifying treatment for Parkinson\u2019s disease dementia: Protocol for a single-centre, randomized, double-blind, placebo-controlled trial","volume":"19","author":"Silveira","year":"2019","journal-title":"BMC Neurol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12883-019-1252-3","article-title":"Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: Protocol for a single-centre, randomized, double-blind, placebo-controlled trial","volume":"19","author":"Silveira","year":"2019","journal-title":"BMC Neurol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/mds.20345","article-title":"Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. dyskinesia in the MPTP\u2010lesioned marmoset model of Parkinson's disease","volume":"20","author":"Silverdale","year":"2005","journal-title":"Mov. Disord."},{"key":"B125","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/mds.20345","article-title":"Topiramate reduces levodopa- induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease","volume":"20","author":"Silverdale","year":"2005","journal-title":"Mov. Disord."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","article-title":"Drug repurposing approach to fight COVID-19 approach to fight COVID-19","volume":"72","author":"Singh","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"B127","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1099\/0022-1317-38-1-97","article-title":"On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride. amantadine hydrochloride","volume":"38","author":"Skehel","year":"1978","journal-title":"J. Gen. Virol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00415-018-8772-4","article-title":"Repurposed drugs for use in Parkinson's disease","volume":"265","author":"Smith","year":"2018","journal-title":"J. Neurol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0377-1237(17)30452-5","article-title":"Sildenafil-Oral medication for erectile dysfunction-a review","volume":"55","author":"Srinath","year":"1999","journal-title":"Med. J. Armed Forces India J. Armed Forces India"},{"key":"B130","doi-asserted-by":"publisher","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","article-title":"\u03b1-Synuclein in Parkinson's disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/cmdc.201100321","article-title":"The evolution of drug discovery: From traditional medicines to modern drugs. By enrique ravi\u00f1a. Drugs. By enrique ravi\u00f1a","volume":"6","author":"Steinhagen","year":"2011","journal-title":"ChemMedChem"},{"key":"B132","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1517\/14656566.2015.1086748","article-title":"Rasagiline for the treatment of Parkinson\u2019s disease: An update","volume":"16","author":"Stocchi","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"B133","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3389\/fnins.2018.00693","article-title":"Emerging treatment approaches for Parkinson's disease","volume":"12","author":"Stoker","year":"2018","journal-title":"Front. Neurosci."},{"key":"B134","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1089\/adt.2017.776","article-title":"Validating the predicted effect of astemizole and ketoconazole using a Drosophila model of Parkinson's disease","volume":"66315","author":"Styczynska-Soczka","year":"2017","journal-title":"Assay. Drug Dev. Technol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning. repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov. Today"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1021\/acschemneuro.7b00478","article-title":"Mechanism underlying the effectiveness of deferiprone in alleviating Parkinson's disease symptoms","volume":"9","author":"Sun","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"B137","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ceb.2020.01.001","article-title":"Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's\u00a0disease. kinase-2 in normal cells and Parkinson's disease","volume":"63","author":"Taylor","year":"2020","journal-title":"Curr. Opin. Cell Biol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/pgmj.2006.054759","article-title":"Levodopa-induced dyskinesia in Parkinson's disease: Clinical features, pathogenesis, prevention and treatment. Features, pathogenesis, prevention and treatment","volume":"83","author":"Thanvi","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"B139","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1358\/dnp.2009.22.2.1303818","article-title":"The value of drug repositioning in the current pharmaceutical market","volume":"22","author":"Tobinick","year":"2009","journal-title":"Drug News Perspect."},{"key":"B140","article-title":"Molecular and clinical prodrome of Parkinson disease: Implications for treatment. Nature reviews | neurology","author":"Tolosa","year":"2010"},{"key":"B141","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fnmol.2018.00165","article-title":"Simvastatin inhibits activation of NADPH oxidase\/p38 MAPK pathway and enhances expression of antioxidant protein in Parkinson disease models","volume":"11","author":"Tong","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"B142","doi-asserted-by":"publisher","first-page":"e13031","DOI":"10.1111\/acel.13031","article-title":"Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease. of Parkinson's disease","volume":"18","author":"Trist","year":"2019","journal-title":"Aging Cell"},{"key":"B143","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-015-1485-1","article-title":"Propagation of alpha-synuclein pathology: Hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. And yet unresolved questions from experimental and human brain studies","volume":"131","author":"Uchihara","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2174\/138920309789351921","article-title":"Biophysics of Parkinson's disease: Structure and aggregation of alpha-synuclein.synuclein. Current protein and peptide science","volume":"10","author":"Uversky","year":"2009","journal-title":"Curr. Protein Pept. Sci."},{"key":"B145","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/ana.20256","article-title":"PINK1 mutations are associated with sporadic early-onset parkinsonism. associated with sporadic early\u2010onset parkinsonism","volume":"56","author":"Valente","year":"2004","journal-title":"Ann. Neurol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/1753193418805249","article-title":"The teratogenic effects of thalidomide on limbs","volume":"44","author":"Vargesson","year":"2019","journal-title":"J. Hand Surg. Eur. Vol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1586\/17512433.2014.966812","article-title":"New treatments for the motor symptoms of Parkinson\u2019s disease","volume":"7","author":"Vijverman","year":"2014","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/mds.23288","article-title":"Defining disease\u2010modifying therapies for PD\u2014A road map for moving forward","volume":"25","author":"Warren Olanow","year":"2010","journal-title":"Mov. Disord."},{"key":"B149","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.euroneuro.2010.02.011","article-title":"The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats","volume":"20","author":"Weber","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/archneur.63.7.969","article-title":"Association of dopamine agonist use with impulse control disorders in Parkinson disease","volume":"63","author":"Weintraub","year":"2006","journal-title":"Arch. Neurol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1208\/s12248-015-9814-9","article-title":"Drug delivery approaches in addressing clinical pharmacology-related issues: Opportunities and challenges. Issues: Opportunities and challenges","volume":"17","author":"Wen","year":"2015","journal-title":"AAPS J."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/mds.23034","article-title":"Long\u2010term antidyskinetic efficacy of amantadine in Parkinson's disease","volume":"25","author":"Wolf","year":"2010","journal-title":"Mov. Disord."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/mds.23687","article-title":"A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.\u2010 blind, placebo\u2010controlled trial of levetiracetam for dyskinesia in Parkinson's disease","volume":"26","author":"Wong","year":"2011","journal-title":"Mov. Disord."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","article-title":"\u03b1-Synuclein toxicity in neurodegeneration: Mechanism and therapeutic strategies. Strategies","volume":"23","author":"Wong","year":"2017","journal-title":"Nat. Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/practneurol-2012-000463","article-title":"When the going gets tough: How to select patients with Parkinson's disease for advanced therapies. Advanced therapies","volume":"13","author":"Worth","year":"2013","journal-title":"Pract. Neurol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/brain\/aws360","article-title":"The cerebellum in Parkinson\u2019s disease","volume":"136","author":"Wu","year":"2013","journal-title":"Brain"},{"key":"B157","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.bbi.2018.01.004","article-title":"Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the \u03b12-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson's disease","volume":"69","author":"Yssel","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"B158","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1517\/13543784.8.5.697","article-title":"Ropinirole in the treatment of Parkinson\u2019s disease","volume":"8","author":"Zesiewicz","year":"1999","journal-title":"Expert Opin. Investig. Drugs investigational drugs"},{"key":"B159","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1196\/annals.1427.023","article-title":"Oxidative stress in Parkinson's disease: A mechanism of pathogenic and therapeutic significance. Pathogenic and therapeutic significance","volume":"1147","author":"Zhou","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1028356\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T07:28:43Z","timestamp":1666769323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1028356\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":159,"alternative-id":["10.3389\/fphar.2022.1028356"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1028356","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"article-number":"1028356"}}